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Abstract
Introduction: Klotho is a transmembrane protein that attenuates insulin/insulin-like growth factor-1 (IGF-1) signalling and appears to be 
involved in ageing. Recent data suggest that soluble a-Klotho (sKlotho) is also elevated in acromegaly. 
The aim of this study was to assess serum levels of sKlotho in patients in relation to the activity of the disease and to compare with the 
control group. 
Material and methods: We studied 55 patients with acromegaly and 29 healthy controls (CG). Patients were divided into three subgroups 
according to minimal GH (growth hormone) concentration during the oral glucose tolerance test (OGTT) and the IGF-1 concentration: 
a surgically cured acromegalic group (SCA), well-controlled acromegalic group (WCA), and active acromegaly group (AA). In all subjects, 
blood samples were taken to assess the concentration of sKlotho, GH, IGF-1, and biochemical markers. 
Results: Soluble a-Klotho was highest in the AA group and lowest in the SCA group. The differences in sKlotho levels were statistically 
significant when the AA group was compared to the SCA, WCA, and CG groups (p = 0.000, p = 0.002, p = 0.001, respectively). There were 
no significant differences in sKlotho levels among the SCA, WCA, and CG groups. sKlotho positively correlated with GH levels in the 
WCA and WCA + SCA groups (r = 0.666, p = 0.009; r = 0.366, p = 0.047, respectively) and with the IGF-1 level in the AA group (r = 0.589, 
p = 0.021). 
Conclusions: sKlotho is increased in active acromegaly and normalises after successful treatment. It could be a new biomarker of acro-
megaly activity. (Endokrynol Pol 2016; 67 (4): 390–396)
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Streszczenie
Wstęp: Klotho to białko transbłonowe, osłabiające sygnał na szlaku insulina/insulinopodobny czynnik wzrostu-1 (IGF-1), biorące praw-
dopodobnie udział w procesie starzenia się organzimu. Najnowsze dane wskazują, że stężenie rozpuszczalnego białka Klotho (sKlotho) 
jest również podwyższone w akromegalii. 
Celem badania była ocena stężenia rozpuszczalnej formy białka Klotho w surowicy pacjentów chorujących na akromegalię w zależności 
od aktywności choroby w porównaniu z grupą kontrolną. 
Materiał i metody: W badaniu wzięło udział 55 pacjentów z akromegalią i 29 zdrowych pacjentów tworzących grupę kontrolną (CG). 
Pacjentów z akromegalią podzielono na trzy podgrupy na podstawie minimalnego stężenia hormonu wzrostu (GH) podczas testu do-
ustnego obciążenia glukozą (OGTT), oraz stężenia IGF-1: grupa wyleczonej operacyjnie akromegalii (SCA), grupa dobrze kontrolowanej 
akromegalii (WCA) i grupa aktywnej akromegalii (AA). U wszystkich osób biorących udział w badaniu pobrano krew celem oznaczenia 
stężenia sKlotho, GH, IGF-1 i parametrów biochemicznych. 
Wyniki: Średnie stężenie rozpuszczalnego białka a-Klotho było największe w grupie AA, a najmniejsze w grupie SCA. Różnice stężeń 
sKlotho były istotne statystycznie, gdy grupę AA porównano z grupą SCA, WCA i CG (p = 0,000, p = 0,002, p = 0,001, odpowiednio). 
Nie stwierdzono istotnych różnic stężenia sKlotho pomiędzy pozostałymi grupami, tj. SCA, WCA i CG. sKlotho korelowało dodatnio 
ze stężeniem GH w grupie WCA i WCA + SCA (r = 0,666, p = 0,009; r = 0,366, p = 0,047, odpowiednio) i stężeniem IGF-1 w grupie AA 
(r = 0,589, p = 0,021). 
Wnioski: Stężenie sKlotho jest podwyższone w aktywnej akromegalii i ulega normalizacji po skutecznym leczeniu. Białko Klotho może 
być nowym markerem aktywności akromegalii. (Endokrynol Pol 2016; 67 (4): 390–396)
Słowa kluczowa: hormon wzrostu; IGF-1; aktywność choroby; akromegalia; a-Klotho
Introduction
Acromegaly is a rare disease, characterised by exces-
sive growth hormone (GH) and insulin-like growth 
factor-1 (IGF-1) secretion. GH excess is due to benign 
adenoma in 99% cases [1]. Currently GH and IGF-1 
(a GH dependent, mainly liver-delivered hormone) are 
the biochemical markers for a confirmed disease and 
also for assessing the activity of the disease. According 
to recent guidelines in patients with typical symptoms 
of acromegaly, a test for IGF-1 concentration should be 
done. If the IGF-1 level is increased, it is obligatory to 
perform OGTT after an administration of 75 g of glu-
cose [2]. The diagnosis and monitoring of the disease 
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could be difficult when two parameters are discrepant. 
It is known that several factors can influence the rela-
tionship between the level of GH and IGF-1, such as 
gender, age, liver disease, and malnutrition. IGF-1 and 
GH are known to have biological and technical limita-
tions [3, 4]. These facts influence long-term follow-up 
of acromegalic patients, as well as an early diagnosis of 
recurrence, and make them difficult. A new sensitive 
and specific biomarker is needed for the diagnosis and 
monitoring of acromegaly.
Klotho is a transmembrane protein, named after 
a Greek goddess. From Greek mythology “Klotho” 
was one of the three Fates, and she was responsible for 
spinning the thread of human life. It was shown that 
Klotho-deficient mice (kl/kl) had a shortened life and 
a lot of disorders caused by human ageing, including 
atherosclerosis, osteoporosis, skin atrophy, and pulmo-
nary emphysema [5]. On the other hand, overexpression 
of Klotho prolongs the lifespan [6, 7]. Various func-
tions of Klotho have been described until now. It is 
known that Klotho protein exists in two forms with 
different functions. Membrane-bound Klotho acts as 
a co-receptor for fibroblast growth factor-23 (FGF-23) 
and consequently has an important role for the renal 
function of FGF-23, serving as a major regulator of 
phosphate homeostasis [8]. Klotho can be enzymatically 
cleaved, shed, and released as soluble a-Klotho into 
blood, urine, and cerebrospinal fluid. An association 
between sKlotho, GH, and IGF-1 secretion has been 
suggested. First, it was revealed that (kl/kl) mice were 
smaller and their somatotrophs showed atrophy and 
a reduced number of secretory granules [5]. Soluble 
a-Klotho could also intensify the activity of calcium 
channels TRVP5/6 and it could be a potential inhibitor of 
action of the insulin and IGF-1 track [6, 8]. Recently, de-
creased sKlotho levels have been observed in children 
with organic growth hormone deficiency (GHD) [9], 
and also a strong association between sKlotho and IGF-1 
was revealed in a study comprising 159 healthy children 
[10]. On the other hand, it was also found that soluble 
a-Klotho is increased in patients with active acromegaly 
and normalised after successful removal of GH-pro-
ducing pituitary adenoma, at least as quickly as IGF-1 
[11, 12]. What is more, the level of sKlotho depends on 
gender and it is higher in women with acromegaly [13]. 
Up to this time, the mechanism that leads to the high 
level of sKlotho in active acromegaly is not clear. It is 
known that in acromegaly there are high levels of FGF-
23, phosphate, and calcitriol and also FGF-23 resistance 
[13–14, 16]. On the other hand, it was shown that the 
high level of sKlotho is a consequence of increased pitui-
tary GH secretion, and higher pituitary transmembrane 
Klotho expression was not observed [7, 12].
The aim of our case-control study was to assess the 
serum levels of soluble a-Klotho in acromegalic patients 
in relation to the activity of disease and to compare 
it with the control group (CG). We also analysed the 
relationship between GH and IGF-1 and serum levels 
of soluble a-Klotho in patients with acromegaly and 
the control group.
Material and methods
We enrolled 55 patients with acromegaly and 29 healthy 
subjects as the control group (CG). The acromegaly pa-
tients, 39 women and 16 men, were divided into three 
groups based on the clinical findings and biochemical 
evaluation (the minimal GH concentration during 
OGTT test and IGF-1 concentration). Normal, according 
to the age and sex, concentration of IGF-1 and GH level 
during OGTT test below 1 µg/L (ng/mL) was used as 
a criterion of cure or good control of the disease.
Eighteen patients with cured acromegaly were 
assigned to the surgically cured acromegalic group 
(SCA). Seventeen patients during the treatment with 
a long-acting somatostatin analogue were in the well-
controlled acromegalic group (WCA). Twenty patients, 
who did not meet the criteria for the cure or good 
control of the disease, were in the active acromegalic 
group (AA). All subjects in the AA and WCA groups 
were treated with long-acting octreotide LAR. In the AA 
group two subjects received a 10 mg/dose, five subjects 
a 20 mg/dose, and 13 subjects a 30 mg/dose. Not all of 
the AA patients received the dose of 30 mg due to drug 
intolerance. In the WCA group six patients received 
a 20 mg/dose and 11 patients a 30 mg/dose. There 
was no statistically significant difference between the 
numbers of patients requiring hormonal replacement 
therapy in each subgroup. Among the study groups 23 
acromegalic patients required the hydrocortisone and 
22 the L-thyroxin replacement. Thirteen acromegalic 
patients with diabetes mellitus type 2 were treated 
by oral hypoglycaemic agents. None of the patients 
received insulin therapy. Nineteen subjects among the 
studied received statin therapy: five in the AA group, 
four in the WCA, and five in the SCA and the CG 
groups, respectively. None of them received substitu-
tion of calcium, or vitamin D. All patients had normal 
liver and kidney function tests at the time of the study. 
All subjects were recruited from the patients of the 
Department of Endocrinology, Diabetes, and Isotope 
Therapy, Wroclaw Medical University. We selected 
a control group (CG) of 29 patients by matching subjects 
and controls by sex and age. The control group showed 
no clinical symptoms of acromegaly and had normal 
value of IGF-1 and GH. The protocol of the study 
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was approved by the local Bioethics Committee, and 
informed consent was obtained from all the subjects.
The analyses were performed based on the division 
into groups. The first division was done on the basis of 
the activity of the disease (AA; WCA; SCA). The second 
classification was used to analyse the differences be-
tween the AA group, a group of patients with cured and 
well-controlled acromegaly (WCA + SCA), and controls 
(CG). The third classification compared the patients 
with acromegaly (AA + WCA + CA) and the control 
group (CG). Body weight (kg), height (m), and blood 
pressure (mmHg) were measured in all patients. The 
body mass index was calculated. The GH concentrations 
were measured by a chemiluminescent immunometric 
method (Immulite 2000, Siemens, USA or Germany). 
Serum IGF-1 level was assessed by radioimmunologic 
assay using an IGF-1-D-RIT-CT kit (BioSource S.A, Niv-
elles, Belgium), normal range: according to the sex and 
age. Vitamin D was assessed only in some patients 
(15 AA, 14 WCA, 16 SCA, and 24 CG) by radioimmuno-
logic assay using a 25OH-Vit.D3-Ria-CT kit (DIAsource, 
Louvain-la-Neuve, Belgium). We used the following 
ranges of 25(OH)D concentrations indicating vitamin 
D deficiency (< 20 ng/mL [< 50 nmol/L]), suboptimal 
status (20–30 ng/mL [50–75 nmol/L]), and optimal status 
(30–50 ng/mL [75–125 nmol/L]). The intra- and inter-
assay coefficients of variation (CVs) were 7.3% and 7.2%, 
respectively. Seasonality was based on the date of the 
blood sample collection. The October-April period cor-
responded to the winter season and the May-September 
period corresponded to the summer season. Serum 
calcium, inorganic phosphate, magnesium, and alkaline 
phosphatase were measured using colorimetric assays 
on an Architect c4000 (Abbott Laboratories, Abbott Park, 
IL, USA). Reference ranges were as follows: calcium 
4.2–5.15 mEq/L; inorganic phosphate 2.7–4.5 mg/dL; 
magnesium 1.6–2.6 mg/dL; and alkaline phosphatase 
40–150 IU/L. Human soluble a-Klotho levels were 
measured by commercially available immunoenzymatic 
method using the Human Soluble a-Klotho Assay Kit-
IBL (Immuno-Biological Laboratories, Japan); measure-
ment range: 93.75–6 000 pg/mL.
Statistical analysis
Statistical analysis was done by the computer program 
Statistica for Windows, version 7.0. Parameter distri-
bution was assessed using Shapiro-Wilk’s test. When 
a distribution was normal with equal statistical vari-
ance, Student’s t test was taken for the assessment of 
the statistically significant differences. Mann-Whitney’s 
U-test was used to assess statistically significant dif-
ferences for other parameters. Pearson’s test or the 
Spearman’s rank correlation test R was used to as-
sess the correlation between traits, depending on the 
kind of distribution. As a level a statistical significance 
a p value < 0.05 was used.
Results
The highest mean body mass was observed in the 
AA group and the lowest in the CG group (Table I). 
We found statistically significant differences between 
groups: AA and CG (p = 0.014); SCA and CG (p = 0.005); 
WCA + SCA and CG (p = 0.009); AA + WCA + SCA 
and CG (p = 0.004). The highest mean height was in the 
AA group, while WCA had the lowest. The comparison 
between the AA group and WCA, SCA, and WCA + SCA 
groups revealed statistically significant differences (p = 
0.023, p = 0.048, p = 0.13, respectively). The SCA group 
had the highest BMI and the CG had the lowest. The 
difference was statistically significant when the CG 
was compared to the WCA, SCA, WCA + SCA, and 
AA + WCA + SCA groups (p = 0.003; p = 0.001; p = 0.001; 
p = 0.003, respectively). We did not find statistically 
significant differences between mean age and mean 
blood pressure among the groups (independent on 
Table I. General characteristics of patients with acromegaly and control group (all groups)
Tabela I. Charakterystyka pacjentów z akromegalią i grupy kontrolnej (wszystkie grupy)
Group No Age 
(years)
Body mass 
[kg]
Height 
[m]
BMI 
[kg/m2]
Heart rate 
[beat/min]
AA 20 50.85 ± 5.24 88.1 ± 21.89* 1.73 ± 0.11#Ÿ⁄ 29.31 ± 5.18 70.45 ± 7.27#
WCA 17 55.35 ± 12.45 81.47 ± 14.44 1.65 ± 0.09 29.73 ± 4.73* 63.35 ± 6.7*Ÿ
SCA 18 54.00 ± 11.52 88.0 ± 14.59* 1.65 ± 0.1 31.71 ± 4.48* 69.39 ± 9.75 
CG 29 47.86 ± 15.76 74.78 ± 14.9 1.67 ± 0.09 26.83 ± 4.53 69.59 ± 5.2
SCA + WCA 35 54.66 ± 11.83 84.83 ± 14.68* 1.66 ± 0.09 30.75 ± 4.65* 66.46 ± 8.83
AA + SCA + WCA 55 53.70 ± 13.6 86.02 ± 17.52* 1.68 ± 0.11 30.23 ± 4.85 * 67.91 ± 8.46
*p < 0.05 compared to CG group; #p < 0.05 compared to WCA group; Ÿp < 0.05 compared to SCA group; ⁄p < 0.05 compared to WCA + SCA group; AA — the 
active acromegalic group; WCA — the well-controlled acromegalic group; SCA — the surgically cured acromegalic group; CG — the control group
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used the division), except a difference of mean systolic 
blood pressure between WCA + SCA vs. CG (p = 0.04). 
The highest mean heat beat was in the AA group and 
the lowest in the WCA group. We found a statistically 
significant difference between AA and WCA (p = 0.006) 
and between WCA vs. SCA and WCA vs. CG (p = 0.052; 
p = 0.004, respectively). 
Soluble a-Klotho was highest in the AA group and 
lowest in the SCA group (Table II). The differences of sol-
uble a-Klotho levels were statistically significant when 
the AA group was compared to the WCA (Fig. 1), SCA 
(Fig. 2), and CG groups (p = 0.002; p = 0.000; p = 0.001, 
respectively). The difference was also statistically sig-
nificant when the AA group was compared to the SCA 
+ WCA group (p = 0.000). There was no significant 
difference in the level of soluble a-Klotho among the 
SCA, WCA, and CG groups. Similarly, the levels of IGF-1 
and IGF-1 ULN were highest in the AA group. The 
differences were statistically significant when the 
AA group was compared to the CG, WCA, SCA, and 
WCA + SCA groups (p = 0.000 for all). We did not observe 
a statistically significant difference between the WCA 
and SCA groups. GH levels were significantly higher 
in the AA group compared to the WCA, SCA, CG, and 
WCA + SCA groups (p = 0.000; p = 0.000; p = 0.000; 
p = 0.024, respectively). The same was observed when 
we compared nadir GH in the AA group to the WCA, 
SCA, CG, and WCA + SCA groups (p = 0.000 for all). 
The highest 25(OH) D levels were found in the CG 
group and the lowest in the AA group (the difference 
was statistically significant, p = 0.012). In the WCA and 
SCA groups 25(OH) D concentrations were also lower 
compared to the CG group; however, the differences 
were not statistically significant (p = 0.109, p = 0.473; 
respectively). The differences in 25(OH)D levels among 
the AA, WCA, and SCA groups were not statistically 
significant. Based on the third classification (AA + WCA 
+ SCA vs. CG), higher 25(OH)D concentrations were 
found in the CG group, and the difference was statisti-
cally significant (p = 0.047).
Calcium concentrations were highest in the AA 
group, but the differences compared to other groups 
were not statistically significant. We also did not find 
any significant differences in magnesium levels among 
the groups. The inorganic phosphate level was highest 
in the AA group and we noticed statistically significant 
differences when the AA group was compared to the 
CG, WCA, SCA, and WCA + SCA groups (p = 0.012; 
p = 0.029; p = 0.015; p = 0.006, respectively) (Table II).
Soluble a-Klotho positively correlated with GH levels 
in the WCA and WCA + SCA groups (r = 0.666, p = 0.009; 
r = 0.366, p = 0.047, respectively) and with nadir GH 
in the AA + WCA + SCA group (r = 0.51, p = 0.000). 
We observed a positive correlation between sKlotho Ta
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and IGF-1 in the AA group (r = 0.589, p = 0.021) (Fig. 3) 
and IGF-1 ULN in the WCA + SCA and AA + WCA + 
SCA groups (r = 0.46, p = 0.009; r = 0.73, p = 0.000, 
respectively). We did not observe any correlation be-
tween sKlotho and anthropometric parameters, but we 
observed a correlation between sKlotho and vitamin D 
(25OHD). sKlotho correlated positively with vitamin D 
in SCA and SCA + WCA groups (r = 0.514, p = 0.020; 
r = 0.439, p = 0.015, respectively). We also found sig-
nificant positive correlation between inorganic phos-
phate levels and IGF-1 in the AA group (r = 0.582, p = 
0.014) and GH concentrations at 0’ in the CG (r = 0.516, 
p = 0.028). Calcium levels correlated negatively with 
GH at 0’ in CG (r = –0.641, p = 0.014.). There was no 
correlation between sKlotho and calcium and magne-
sium levels. Soluble Klotho correlated positively with 
inorganic phosphate in the AA + WCA + SCA groups 
(r = 0.419, p = 0.013).
Discussion
Recent studies suggest that soluble a-Klotho is elevated 
in patients with active acromegaly and decreases to-
wards the normal after successful surgical treatment. 
Our present study confirms the earlier findings of 
highly significant difference in sKlotho levels in pa-
tients with active acromegaly to other groups [11–13]. 
The difference was statistically significant when we 
compared the AA group to the SCA and WCA groups 
as well as to the CG group, so it was independent of 
methods of therapy or health conditions. The lowest 
level of sKlotho was observed in patients with surgically 
cured acromegaly. It had been suggested before that 
elevated sKlotho is specific for GH-positive adenomas 
as a consequence of systemic action of GH rather than 
local sKlotho expression by the adenoma. Neidert et 
al. presented patients with acromegaly having signifi-
Figure 3. Correlation between soluble a-Klotho and IGF-1 in the 
active acromegaly (AA) group (r = 0.589, p = 0.021)
Rycina 3. Korelacja stężenia białka Klotho ze stężeniem IGF-1 
w aktywnej akromegalii (AA) (r = 0,589, p = 0,021)
Figure 1. Concentration of soluble a-Klotho in relation to the 
activity of acromegaly (AA — active acromegaly group, WCA — 
the well-controlled acromegalic group). AA vs. WCA, p = 0.002
Rycina 1. Stężenie rozpuszczalnego białka Klotho w zależności 
od aktywności akromegalii (AA — grupa aktywnej akromegali, 
WCA — grupa dobrze kontrolowanej akromegalii). AA vs. WCA, 
p = 0,002
Figure 2. Concentration of soluble a-Klotho in relation to the 
activity of acromegaly (AA — active acromegaly group, SCA — 
surgical cured acromegalic group). AA vs. SCA, p = 0.000
Rycina 2. Stężenie rozpuszczalnego białka Klotho w zależności 
od aktywności akromegalii (AA — grupa aktywnej akromegalii, 
SCA — grupa wyleczonej operacyjnie akromegalii). AA vs. SCA, 
p = 0,000
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cantly higher levels of sKlotho compared to the control 
group patients with other adenomas, and the level of 
sKlotho declined after surgery during early as well as 
late follow-up [11]. The mechanism by which sKlotho 
increased in active acromegaly is unclear. It could be a 
consequence of distinct transcript or a result of ectodo-
main shedding of membrane Klotho (mKlotho). Two 
members of the ‘A Disintegrin and Metalloproteinase’ 
(ADAM) family, ADAM10 and ADAM17 (a-secretases), 
have been suggested as responsible enzymes. It is 
speculated that the activity of these enzymes could 
by regulated directly by GH or indirectly by factors or 
proteolytic activity induced by GH [15–17]. Varewijck 
et al. observed a positive correlation between sKlotho 
and IGF-1 in the active acromegaly group. The same 
correlation was observed in our study. They suggest 
two potential causes for the relation between IGF-1 
and sKlotho. Firstly, sKlotho could be an independent 
marker of the activity of acromegaly as IGF-1. On the 
other hand, some researchers tried to explain that that 
high level of sKlotho is a consequence of the adaptation 
mechanism, by which the body attenuates increased 
IGF-1 action. It has been observed that sKlotho may 
suppress the activation of IGF-1 receptor (IGF1R) [6, 18].
High levels of sKlotho can be observed without 
changes in mKlotho expression. In this study we 
observed a statistically significant increased level 
of phosphate in the AA group compared to the CG, 
WCA, SCA, and WCA + SCA groups and a positive 
correlation between sKlotho and phosphate in the 
AA + SCA + WCA groups. Acromegaly has unique 
biochemical and endocrine characteristics. High serum 
phosphate and FGF23 levels are observed despite the 
enhanced GFR, and it also leads to insulin resistance 
(IR) and hyperglycaemia. What is more, a high level of 
calcitriol is also detected. It is suggested that increased 
mKlotho-proteolytic enzymes activity could lead to 
decreasing mKlotho and to impaired FGF23 signalling, 
which explains FGF23 resistance. As a consequence of 
increased activity of enzymes, sKlotho is increased and 
contributes to IR [7]. As we observed in our previous 
study 25(OH)D correlated positively with IGF-1 only 
in AA group [19]. It confirmed that the mechanism of 
regulation of FGF-23-membrane-Klotho complex and 
sKlotho excess is different in acromegaly.
The Klotho gene was identified as an aging suppres-
sor gene in mice, so it suggests that the level of sKlotho 
should be decreased with age in healthy subjects. We 
did not observe any negative correlation between sK-
lotho and age in our groups. These results are consist-
ent with earlier ones and confirm an autonomous GH 
secretion of sKlotho [11].
It seems that sKlotho could be a good indicator of 
activity of acromegaly but there are some questions 
related to its use as a marker in acromegaly. First of 
all, different assays were used to determine sKlotho in 
human serum. The Elisa system seems to be the best 
option but the three commercial assays differ in qual-
ity. Additionally, the normal range for serum levels of 
sKlotho cannot be known. Neidert et al. measured the 
level of sKlotho in the sera of 26 volunteers and the 
median was 596 pg/mL (506–734) [12]. On the other 
hand, Yamazaki et al. reported the reference serum of 
sKlotho levels in 142 volunteers: the range of values was 
from 239 to 1266 pg/mL (mean ± SD: 526 ± 146 pg/mL). 
In their study the levels were not influenced by gender 
or by skeletal metabolism but correlated negatively 
with serum creatinine level and age. What is more, 
additional analysis with Asiatic children (23 boys and 
16 girls) revealed significantly greater concentrations of 
sKlotho (952 ± 282 pg/mL) [20]. In another study it was 
shown that sKlotho has a circadian rhythm and the low-
est concentration is around midnight and the highest 
is in the early morning [21]. Some factors such as age, 
gender, BMI, and renal function can influence the level 
of soluble a-Klotho. In our study we did not observe 
any correlation between soluble a-Klotho and any of 
the anthropometric measurements. The previous study 
showed no influence of age, and this was explained by 
the autonomy of GH adenoma [11]. The impact of BMI 
is unclear. Semba et al. presented no influence of BMI 
on the concentration of sKlotho [22]. In another small 
study it was noticed that anorexia nervosa as well as 
obesity could be responsible for lower levels of sKlotho 
[23]. It is very important to remember that acromegaly 
is also associated with a decrease in fat mass and an in-
crease in lean body mass. This is a result of the lipolytic 
effect of GH. In this situation BMI does not reflect an 
increased fat mass as in the normal population [24]. In 
fact, attenuation of daily activity could be connected 
with the decrease in sKlotho [25]. It was also observed 
that levels of IGF-1 and soluble a-Klotho are different 
with regard to gender. Sze at al. showed that IGF-1 
had a tendency to be higher in men whereas soluble 
a-Klotho levels were greater in females. Lower levels 
of IGF-1 are caused by the influence of oestrogens in 
premenopausal women [13].
To sum up, soluble a-Klotho is increased in patients 
with active acromegaly and normalises after successful 
treatment. It could be an independent new biomarker 
of the activity of acromegaly. More study is needed to 
analyse the influence of gender, BMI, age, and other 
factors on the level of sKlotho. Moreover, the standardi-
sation of sKlotho assays and normal range is required.
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